China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Google Secures Pentagon AI Deal for Classified Projects 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
SAN DIEGO and TORONTO, Feb. 18, 2016 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the 2016 RBC Capital Markets Global Healthcare Conference at 10:00 a.m. ET on Wednesday, February 24, 2016 in New York City.
A live webcast of the fire-side chat can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/74205320763.cfm
The audio webcast will be archived shortly after the live event and will be available for 30 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Inc. Greg Chow, CFO 647-479-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
